HLS Therapeutics Inc. (HLS.TO)
CAD 4.24
(-0.7%)
CAD 4.24
(-0.7%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -27.53 Million USD | -16.67% |
| 2022 | -23.59 Million USD | -79.9% |
| 2021 | -13.11 Million USD | 14.44% |
| 2020 | -15.33 Million USD | 21.59% |
| 2019 | -19.55 Million USD | 21.18% |
| 2018 | -24.8 Million USD | -306.86% |
| 2017 | -6.09 Million USD | -596.85% |
| 2016 | -874.93 Thousand USD | 49.5% |
| 2015 | -1.73 Million USD | -113.62% |
| 2014 | 12.71 Million USD | 30.67% |
| 2013 | 9.73 Million USD | -42.3% |
| 2012 | 16.86 Million USD | 40.76% |
| 2011 | 11.98 Million USD | 1732.87% |
| 2010 | -733.88 Thousand USD | -128.74% |
| 2009 | 2.55 Million USD | 145.27% |
| 2008 | -5.64 Million USD | -174.27% |
| 2007 | 7.59 Million USD | 479.72% |
| 2006 | 1.31 Million USD | -86.22% |
| 2005 | 9.5 Million USD | 209.42% |
| 2004 | -8.68 Million USD | -400.86% |
| 2003 | 2.88 Million USD | -2.01% |
| 2002 | 2.94 Million USD | 1.31% |
| 2001 | 2.9 Million USD | 27.14% |
| 2000 | 2.28 Million USD | -43.83% |
| 1999 | 4.07 Million USD | 161.45% |
| 1998 | -6.62 Million USD | -479.44% |
| 1997 | 1.74 Million USD | -74.68% |
| 1996 | 6.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -5.68 Million USD | 6.94% |
| 2024 Q1 | -6.1 Million USD | -13.05% |
| 2023 FY | -27.53 Million USD | -16.67% |
| 2023 Q1 | -5.79 Million USD | 9.91% |
| 2023 Q2 | -9.43 Million USD | -62.93% |
| 2023 Q3 | -6.9 Million USD | 26.87% |
| 2023 Q4 | -5.4 Million USD | 21.74% |
| 2022 Q1 | -3.61 Million USD | 13.66% |
| 2022 FY | -23.59 Million USD | -79.9% |
| 2022 Q3 | -4.41 Million USD | 51.77% |
| 2022 Q2 | -9.14 Million USD | -152.85% |
| 2022 Q4 | -6.42 Million USD | -45.78% |
| 2021 Q3 | -1.97 Million USD | 9.92% |
| 2021 Q1 | -4.75 Million USD | 34.69% |
| 2021 FY | -13.11 Million USD | 14.44% |
| 2021 Q2 | -2.19 Million USD | 53.78% |
| 2021 Q4 | -4.18 Million USD | -111.62% |
| 2020 Q3 | -1.73 Million USD | 73.23% |
| 2020 Q4 | -7.27 Million USD | -319.97% |
| 2020 Q2 | -6.47 Million USD | -4303.9% |
| 2020 FY | -15.33 Million USD | 21.59% |
| 2020 Q1 | 154 Thousand USD | 101.26% |
| 2019 Q1 | -3.7 Million USD | -1103.52% |
| 2019 Q2 | -1.63 Million USD | 55.95% |
| 2019 FY | -19.55 Million USD | 21.18% |
| 2019 Q4 | -12.22 Million USD | -511.61% |
| 2019 Q3 | -1.99 Million USD | -22.5% |
| 2018 Q2 | -563 Thousand USD | 88.45% |
| 2018 FY | -24.8 Million USD | -306.86% |
| 2018 Q4 | 369 Thousand USD | 101.87% |
| 2018 Q3 | -19.73 Million USD | -3405.51% |
| 2018 Q1 | -4.87 Million USD | 6.79% |
| 2017 Q1 | -266.95 Thousand USD | 9.15% |
| 2017 FY | -6.09 Million USD | -596.85% |
| 2017 Q4 | -5.23 Million USD | -1547.08% |
| 2017 Q3 | -317.6 Thousand USD | -27.49% |
| 2017 Q2 | -249.12 Thousand USD | 6.68% |
| 2016 Q3 | -98.11 Thousand USD | 57.69% |
| 2016 FY | -874.93 Thousand USD | 49.5% |
| 2016 Q2 | -231.87 Thousand USD | 10.15% |
| 2016 Q1 | -258.08 Thousand USD | -25.66% |
| 2016 Q4 | -293.83 Thousand USD | -199.47% |
| 2015 Q2 | -61.22 Thousand USD | 95.28% |
| 2015 Q3 | -246.55 Thousand USD | -302.7% |
| 2015 Q4 | -205.37 Thousand USD | 16.7% |
| 2015 FY | -1.73 Million USD | -113.62% |
| 2015 Q1 | -1.29 Million USD | -125.21% |
| 2014 FY | 12.71 Million USD | 30.67% |
| 2014 Q4 | 5.14 Million USD | 53.99% |
| 2014 Q1 | 2.85 Million USD | -6.68% |
| 2014 Q2 | 1.47 Million USD | -48.49% |
| 2014 Q3 | 3.33 Million USD | 126.7% |
| 2013 Q3 | 2.39 Million USD | 225.36% |
| 2013 Q1 | 3.57 Million USD | -18.95% |
| 2013 FY | 9.73 Million USD | -42.3% |
| 2013 Q4 | 3.06 Million USD | 27.99% |
| 2013 Q2 | 735.62 Thousand USD | -79.42% |
| 2012 Q4 | 4.4 Million USD | 2.28% |
| 2012 FY | 16.86 Million USD | 40.76% |
| 2012 Q3 | 4.31 Million USD | -0.08% |
| 2012 Q2 | 4.31 Million USD | 18.54% |
| 2012 Q1 | 3.63 Million USD | -5.73% |
| 2011 Q1 | 3.64 Million USD | 37.8% |
| 2011 Q2 | 2.63 Million USD | -27.84% |
| 2011 Q3 | 2.24 Million USD | -14.68% |
| 2011 Q4 | 3.86 Million USD | 71.86% |
| 2011 FY | 11.98 Million USD | 1732.87% |
| 2010 Q2 | -2.2 Million USD | -1012.62% |
| 2010 FY | -733.88 Thousand USD | -128.74% |
| 2010 Q1 | -198.15 Thousand USD | -109.65% |
| 2010 Q4 | 2.64 Million USD | 383.67% |
| 2010 Q3 | -933.32 Thousand USD | 57.67% |
| 2009 Q3 | -1 Million USD | -145.07% |
| 2009 Q2 | 2.21 Million USD | 388.25% |
| 2009 FY | 2.55 Million USD | 145.27% |
| 2009 Q4 | 2.05 Million USD | 305.3% |
| 2009 Q1 | -769.77 Thousand USD | 90.9% |
| 2008 FY | -5.64 Million USD | -174.27% |
| 2008 Q4 | -8.45 Million USD | -791.16% |
| 2008 Q3 | 1.22 Million USD | 22.91% |
| 2008 Q2 | 995.28 Thousand USD | 52.67% |
| 2008 Q1 | 651.89 Thousand USD | -71.8% |
| 2007 Q1 | 1.28 Million USD | 1424.01% |
| 2007 FY | 7.59 Million USD | 479.72% |
| 2007 Q4 | 2.31 Million USD | 48.45% |
| 2007 Q3 | 1.55 Million USD | -25.4% |
| 2007 Q2 | 2.08 Million USD | 63.03% |
| 2006 Q1 | 494.93 Thousand USD | -93.87% |
| 2006 Q2 | 530.42 Thousand USD | 7.17% |
| 2006 Q3 | 178.21 Thousand USD | -66.4% |
| 2006 Q4 | 84.01 Thousand USD | -52.86% |
| 2006 FY | 1.31 Million USD | -86.22% |
| 2005 Q2 | 467.73 Thousand USD | 8.19% |
| 2005 Q3 | 495.41 Thousand USD | 5.92% |
| 2005 Q4 | 8.06 Million USD | 1528.8% |
| 2005 Q1 | 432.33 Thousand USD | 104.33% |
| 2005 FY | 9.5 Million USD | 209.42% |
| 2004 Q3 | -99.9 Thousand USD | -118.6% |
| 2004 Q4 | -9.99 Million USD | -9904.02% |
| 2004 FY | -8.68 Million USD | -400.86% |
| 2004 Q1 | 806.11 Thousand USD | 19.93% |
| 2004 Q2 | 537.06 Thousand USD | -33.38% |
| 2003 Q1 | 557.52 Thousand USD | 87.76% |
| 2003 FY | 2.88 Million USD | -2.01% |
| 2003 Q4 | 672.16 Thousand USD | 2696.34% |
| 2003 Q3 | -25.88 Thousand USD | -101.58% |
| 2003 Q2 | 1.64 Million USD | 194.65% |
| 2002 FY | 2.94 Million USD | 1.31% |
| 2002 Q4 | 296.94 Thousand USD | -63.64% |
| 2002 Q3 | 816.73 Thousand USD | 3.14% |
| 2002 Q2 | 791.9 Thousand USD | -26.1% |
| 2002 Q1 | 1.07 Million USD | 36.62% |
| 2001 Q1 | 688.71 Thousand USD | 253.63% |
| 2001 FY | 2.9 Million USD | 27.14% |
| 2001 Q4 | 784.35 Thousand USD | -19.12% |
| 2001 Q3 | 969.81 Thousand USD | 99.48% |
| 2001 Q2 | 486.17 Thousand USD | -29.41% |
| 2000 Q2 | 472.6 Thousand USD | -37.59% |
| 2000 Q1 | 757.29 Thousand USD | -55.2% |
| 2000 FY | 2.28 Million USD | -43.83% |
| 2000 Q4 | 194.75 Thousand USD | -78.25% |
| 2000 Q3 | 895.23 Thousand USD | 89.43% |
| 1999 Q4 | 1.69 Million USD | 125.67% |
| 1999 Q2 | 881.85 Thousand USD | 20.97% |
| 1999 Q1 | 728.96 Thousand USD | 110.29% |
| 1999 FY | 4.07 Million USD | 161.45% |
| 1999 Q3 | 749.04 Thousand USD | -15.06% |
| 1998 FY | -6.62 Million USD | -479.44% |
| 1998 Q4 | -7.08 Million USD | -981.91% |
| 1998 Q2 | 68.06 Thousand USD | -94.32% |
| 1998 Q1 | 1.19 Million USD | 0.0% |
| 1998 Q3 | -655.09 Thousand USD | -1062.41% |
| 1997 Q3 | 70.97 Thousand USD | -83.7% |
| 1997 FY | 1.74 Million USD | -74.68% |
| 1997 Q2 | 435.44 Thousand USD | -56.52% |
| 1997 Q1 | 1 Million USD | 0.0% |
| 1996 FY | 6.9 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aurora Cannabis Inc. | -69.32 Million CAD | 60.288% |
| Avicanna Inc. | -8.74 Million CAD | -214.892% |
| Avant Brands Inc. | -5.07 Million CAD | -443.018% |
| Cardiol Therapeutics Inc. | -28.12 Million CAD | 2.123% |
| Crescita Therapeutics Inc. | -1.98 Million CAD | -1286.254% |
| Knight Therapeutics Inc. | -16.83 Million CAD | -63.534% |
| MediPharm Labs Corp. | -13.08 Million CAD | -110.433% |
| OrganiGram Holdings Inc. | -229.47 Million CAD | 88.003% |
| Canopy Growth Corporation | -657.26 Million CAD | 95.811% |
| Willow Biosciences Inc. | -13.02 Million CAD | -111.306% |
| Auxly Cannabis Group Inc. | -44.51 Million CAD | 38.148% |